[Preprint] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (2022) Killingley et al

Discussion in 'Epidemics (including Covid-19, not Long Covid)' started by Milo, Feb 5, 2022.

Tags:
  1. Milo

    Milo Senior Member (Voting Rights)

    Messages:
    2,108
    This is the paper linked to the experiment of inoculating young adults with COVID early in 2020.

    Abstract:

    To establish a novel SARS-CoV-2 human challenge model, 36 volunteers aged 18-29 years without evidence of previous infection or vaccination were inoculated with 10 TCID50 of a wild-type virus (SARS-CoV-2/human/GBR/484861/2020) intranasally.

    Two participants were excluded from per protocol analysis due to seroconversion between screening and inoculation. Eighteen (~53%) became infected, with viral load (VL) rising steeply and peaking at ~5 days post-inoculation.

    Virus was first detected in the throat but rose to significantly higher levels in the nose, peaking at ~8.87 log10 copies/ml (median, 95% CI [8.41,9.53).

    Viable virus was recoverable from the nose up to ~10 days post-inoculation, on average. There were no serious adverse events.

    Mild-to-moderate symptoms were reported by 16 (89%) infected individuals, beginning 2-4 days post-inoculation.

    Anosmia/dysosmia developed more gradually in 12 (67%) participants.

    No quantitative correlation was noted between VL and symptoms, with high VLs even in asymptomatic infection, followed by the development of serum spike-specific and neutralising antibodies.

    However, lateral flow results were strongly associated with viable virus and modelling showed that twice-weekly rapid tests could diagnose infection before 70-80% of viable virus had been generated.

    Thus, in this first SARS-CoV-2 human challenge study, no serious safety signals were detected and the detailed characteristics of early infection and their public health implications were shown. ClinicalTrials.gov identifier: NCT04865237

    Link to paper here
    Link to the related Science article here
     
    Peter Trewhitt and Andy like this.
  2. rvallee

    rvallee Senior Member (Voting Rights)

    Messages:
    12,492
    Location:
    Canada
    That's weird. Or maybe just the result of rigorous record-keeping. It wouldn't be much of a surprise if most "asymptomatic" cases are actually mild symptoms that people simply shrug off, or simply don't mention. Otherwise this is much higher than usually reported.
     

Share This Page